Drugs / ENSITUXIMAB
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01834235 | Apr 2013 → Mar 2017 | malignant pancreatic neoplasm | Precision Biologics, Inc | Terminated | Missed primary |
| Phase 1/2 | NCT01040000 | Jan 2012 → Mar 2017 | colorectal cancer, malignant pancreatic neoplasm | Precision Biologics, Inc | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ENSITUXIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743013 ↗ |
| Known as | NEO-101 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743013 ↗ |
| Known as | NEO-102 | “investigational agent NEO-102 (NPC-1C)” NCT01834235 ↗1“NPC-1C/NEO-102” NCT01040000 ↗ |
| Known as | NPC-1C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01040000 ↗ |
| Action | Deplete | “the antibody killed tumor cells in some colon and pancreatic cancers” NCT01040000 ↗ |
| Modality | Monoclonal antibody | “NPC-1C is a monoclonal antibody” NCT01040000 ↗ |
| Route | Intravenous | “NPC-1C will be given intravenously (by vein)” NCT01040000 ↗ |
| Target | MUC5AC | “NPC-1C, an antibody directed against MUC5AC” PMID 36602796 ↗ Jan 2023 |